Radioactivity in blood and urine following intraperitoneal instillation of chromic phosphate in patients with and without ascites.
Systemic distribution of radioactive colloidal chromic phosphate P 32 after intraperitoneal instillation was studied in 10 patients with ovarian or endometrial malignancies. Seven patients without ascites received chromic phosphate P 32 for positive peritoneal washings, rupture of the capsule of the cyst during operation, or minimal Stage III disease. Three patients received chromic phosphate P 32 for recurrent ascites after multiple abdominal paracenteses. Blood and urine radioactivity measurements were performed at selected intervals. There was a clear statistically significant difference (p less than 0.01) between chromic phosphate P 32 activity levels in whole blood, red blood cells, and plasma in patients with and without ascites.
D000328:Adult; D000368:Aged; D001201:Ascites / Q000097:blood / Q000150:complications / Q000532:radiotherapy / Q000652:urine; D001918:Brachytherapy; D002857:Chromium / Q000097:blood / Q000652:urine; D017608:Chromium Compounds; D005260:Female; D006801:Humans; D007700:Kinetics; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000097:blood / Q000150:complications / Q000532:radiotherapy* / Q000652:urine; D010710:Phosphates / Q000097:blood / Q000652:urine; D010761:Phosphorus Radioisotopes / Q000097:blood / Q000627:therapeutic use* / Q000652:urine; D014594:Uterine Neoplasms / Q000097:blood / Q000150:complications / Q000532:radiotherapy* / Q000652:urine
D017608:Chromium Compounds; D010710:Phosphates; D010761:Phosphorus Radioisotopes; D002857:Chromium; C509369:chromic phosphate